Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
T., Torriani, M., Kleiner, D
To protect your sleep hygiene: Avoid screens two hours before bed
doi: 10.1016/j.biochi.2020.03.015, 71
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
